Treatment with a selenium-platinum compound induced T-cell acute lymphoblastic leukemia/lymphoma cells apoptosis through the mitochondrial signaling pathway

FEIFEI WU1, WEI CAO2, HUAPING XU2, MINGXIA ZHU1, JING WANG1 and XIAOYAN KE1

1Department of Hematology and Lymphoma Research Center, Peking University Third Hospital, Beijing 100191; 2Key Laboratory of Organic Optoelectronics and Molecular Engineering, Department of Chemistry, Tsinghua University, Beijing 100084, P.R. China

Received October 2, 2015; Accepted December 2, 2016

DOI: 10.3892/ol.2017.5666

Abstract. T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) is an aggressive hematological disorder that is sensitive to chemotherapy; however, it exhibits frequent relapse rates. Platinum-containing therapeutics are the first-line salvage regimens used in the treatment of relapsed or refractory T-ALL/LBL. The selenium-platinum compound EG-Se/Pt is obtained from the combination of selenium-containing molecules (EG-Se) with cisplatin (CDDP); however, its anticancer properties have been poorly investigated. In the present study, the Cell Counting Kit-8 assay was used to evaluate the inhibitory effect of treatment with EG-Se/Pt on cell viability. Cell cycle distribution, apoptosis, reactive oxygen species (ROS) content and the mitochondrial membrane potential were analyzed using flow cytometry. Intracellular platinum content was detected using inductively coupled plasma mass spectrometry. Caspase activity was determined using a colorimetric assay. The expression of several proteins associated with apoptosis was analyzed using western blotting. The results of the present study demonstrated that treatment with EG-Se/Pt increased the inhibition of Jurkat and Molt-4 T-ALL/LBL cell viability compared with CDDP, and induced apoptosis and cell cycle arrest. The intracellular platinum content of T-ALL/LBL cells treated with EG-Se/Pt was increased compared with that of T-ALL/LBL cells treated with CDDP. EG-Se/Pt-induced apoptosis was mediated by caspase and ROS levels through the activation of the mitochondrial signaling pathway. The results of the present study suggest that EG-Se/Pt is a potential therapeutic candidate for the treatment of T-ALL/LBL.

Introduction

T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) is an aggressive non-Hodgkin lymphoma arising from T progenitor cells or thymic T cells in diverse differentiation stages. Although complete remission rates with high-dose regimens are between 80 and 90%, >30% of adults relapse following intensive consolidation (1). The survival outcomes of patients with T-ALL/LBL remain unsatisfactory. Platinum (Pt)-containing chemotherapeutic agents serve an important role in the treatment of T-cell lymphomas, particularly in the salvage treatment of relapsed or refractory T-ALL/LBL (2-4). Cis-diamminedichloridoplatinum (II) (CDDP), or cisplatin, is one of the best known and most widely used Pt-containing chemotherapeutic drugs. Since the first clinical trial in 1971 (5), >10,000 of patients with sarcomas, lymphomas and solid tumors have benefitted from treatment with CDDP (5,6). CDDP is able to induce cell apoptosis through extrinsic and intrinsic signaling pathways, and affects the protein kinase B (PKB), c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase signaling pathways; however, its severe side effects and drug resistance limit further applications (6,7).

To overcome these obstacles, the structure of CDDP has been modified and reconstructed to synthesize novel antitumor agents including carboplatin or oxaliplatin (6,7).

Selenium (Se) is an essential trace element with a number of biological functions (8). Previous epidemiological and clinical studies have demonstrated that Se is an effective chemotherapeutic agent in prostate, lung, colon, liver and esophageal cancer and multiple lymphomas (8). Se-containing compounds are able to induce tumor cell cycle arrest and apoptosis, through the expression of cyclin-dependent kinase inhibitor 1A and 1B, the inhibition of PKB, extracellular-signal-regulated kinase 1/2 and JNK1/2, and the generation of reactive oxygen species (ROS) (9,10). Certain Se-based compounds are able to selectively kill cancer cells in vitro and in vivo (11,12). ROS have...
been reported to induce apoptosis via a series of downstream signaling pathways including a mitochondrial cascade (13,14). Furthermore, increased ROS levels in cancer cells serve a role in the selective killing of cancer cells by antitumor agents (12,15). Chemists from Tsinghua University (Beijing, China) have developed a novel compound, EG-Se/Pt, based on the coordination of Se-containing small molecules (EG-Se) and CDDP, which demonstrates broad-spectrum anticancer activity in breast, lung and liver cancer cell lines, and selectivity of tumor cells (12). The present study demonstrates that EG-Se/Pt kills T-LBL/ALL cells by inducing cell cycle arrest and ROS-mediated apoptosis through the mitochondrial signaling pathway.

Materials and methods

Cells and cell culture. The human T-ALL/LBL cell lines Jurkat and Molt-4 were obtained from the American Type Culture Collection (Manassas, VA, USA), and were cultured in RPMI 1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 2 mM L-glutamine, 10% fetal bovine serum (HyClone; GE Healthcare Life Sciences, Logan, UT, USA), 100 units/ml penicillin and 100 µg/ml streptomycin. Cells were routinely cultured at 37°C in a humidified incubator containing 5% CO₂ and were passaged between every 2 and 3 days.

Antibodies and reagents. Mouse monoclonal antibodies specific for cytochrome c (1:200; cat. no. sc-13156) and β-actin (1:200; cat. no. sc-47778) were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Rabbit monoclonal antibodies against apoptosis regulator Bcl-2 (1:1,000; cat. no. 4223) and cleaved caspase-3 (1:1,000; cat. no. 9664), and rabbit polyclonal antibodies against apoptosis regulator Bax (1:1,000; cat. no. 2772), cleaved caspase-9 (1:1,000; cat. no. 9505) and cleaved poly(ADP-ribose) polymerase (PARP; 1:1,000; cat. no. 9542) were from Cell Signaling Technology, Inc. (Danvers, MA, USA). Rabbit monoclonal antibody against apoptotic protease-activating factor 1 (Apaf-1) (1:1,000; cat. no. ab32337) was from Abcam (Cambridge, UK). IRDye 800CW-conjugated goat polyclonal anti-rabbit and anti-mouse immunoglobulin (IgG) secondary antibodies (cat. nos. 925-32211 and 925-32210, respectively; IRDye 800CW-conjugated goat polyclonal anti-rabbit and anti-mouse immunoglobulin (IgG) secondary antibodies (cat. nos. 925-32211 and 925-32210, respectively; cat. no. 9505) and cleaved poly(ADP-ribose) polymerase (PARP; 1:1,000; cat. no. 9542) were from Cell Signaling Technology, Inc. (Danvers, MA, USA). Rabbit monoclonal antibody against apoptotic protease-activating factor 1 (Apaf-1) (1:1,000; cat. no. ab32337) was from Abcam (Cambridge, UK). IRDye 800CW-conjugated goat polyclonal anti-rabbit and anti-mouse immunoglobulin (IgG) secondary antibodies (cat. nos. 925-32211 and 925-32210, respectively; cat. no. 9505) and cleaved poly(ADP-ribose) polymerase (PARP; 1:1,000; cat. no. 9542) were from Cell Signaling Technology, Inc. (Danvers, MA, USA).

Molecular Technologies, Inc., Kumamoto, Japan) was used to study apoptosis according to the manufacturer's protocol. The activity of caspase-3 and caspase-9 activity measured using a Colorimetric Assay kit (Nanjing KeyGen Biotech Co., Ltd.) according to the manufacturer's protocol. The activity of caspase-3 or caspase-9 was determined as the optical density at 405 nm (OD₄₀₅) in the experimental group/OD₄₀₅ in the control group using a microplate reader.
Evaluation of mitochondrial membrane potential (MMP). Cells in 6-well plates (1x10^6 cells/well) were treated with EG-Se/Pt and then harvested, washed with PBS and stained with 5,5', 6.6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolyl-carbocyanine iodide (JC-1; Mitochondrial Membrane Potential assay kit; Beyotime Institute of Biotechnology) working solution at 37°C for 20 min in an incubator. The samples were analyzed using a FACSCalibur cytometer. CellQuest Pro software was used for data acquisition and analysis.

Measurement of ROS. Following treatment with EG-Se/Pt, 1x10^5 cells were washed three times with PBS and incubated with 5-(and-6)-chloromethyl-2,7'-dichlorodihydrofluorescein diacetate, acetyl ester (Beyotime Institute of Biotechnology) in an incubator for 20 min at 37°C. The samples were processed using flow cytometry to measure the level of intracellular ROS. CellQuest software was used for data acquisition and analysis.

Western blotting analysis. Following treatment with EG-Se/Pt, total cellular proteins were obtained using RIPA buffer (Applygen Technologies, Inc.). Mitochondrial and cytosolic proteins were obtained using the Cell Mitochondria Isolation kit (Beyotime Institute of Biotechnology) according to the manufacturer’s protocol, followed by lysis with RIPA buffer. 30 µg protein was added per lane and proteins were separated by SDS-PAGE on a 10% gel and transferred onto nitrocellulose membranes. Following blocking with 5% bovine serum albumin (Amresco, Solon, OH, USA) at room temperature for 1 h, the membranes were sequentially incubated with primary antibodies overnight at 4°C and then with IRDye 800CW-conjugated goat (polyclonal) anti-rabbit/anti-mouse IgG secondary antibody for 1 h at room temperature. Fluorescent bands were visualized using an Odyssey infrared imaging system (LI-COR Biosciences), and the gray values were analyzed using Odyssey software (version 3.0; LI-COR Biosciences). β-actin was used as a loading control.

Statistical analysis. Values are presented as the mean ± standard deviation of 6 repeats for each experiment. Protein expression comparisons of the control and treated groups were analyzed by densitometry using Gel-Pro Analyzer 32 software (Media Cybernetics, Inc., Rockville, MD, USA). Comparisons were made using a one-way analysis of variance followed by Bonferroni's test or a Student's t-test. Statistical analysis was performed using Prism software (version 5.01; GraphPad Software, Inc., La Jolla, CA, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

Treatment with EG-Se/Pt inhibits the viability of Jurkat and Molt-4 cells, and exhibits increased toxicity in comparison with CDDP and EG-Se. A novel stable Pt-based complex, EG-Se/Pt, has been developed and its structure is presented in Fig. 1. To evaluate the potential therapeutic efficacy of EG-Se/Pt in the treatment of T-ALL/LBL, Jurkat and Molt-4 cell lines were used. Cell viability was measured using the CCK-8 assay. The results demonstrated that EG-Se/Pt inhibited Jurkat and Molt-4 cell viability in a dose- and time-dependent manner (Fig. 2A and B).

The cell lines were also treated with EG-Se and CDDP separately. EG-Se/Pt exhibited markedly increased toxicity towards cancer cells compared with CDDP and EG-Se (Fig. 2C and D; P<0.01). The half-maximal inhibitory concentration values at 24 h for EG-Se/Pt and CDDP were 33.75 and 40.28 µM, respectively, in Jurkat cells, and 24.93 and 36.39 µM, respectively, in Molt-4 cells (Fig. 2E; P<0.01). These results demonstrate that Jurkat and Molt-4 cells exhibit markedly increased sensitivity to EG-Se/Pt compared with to CDDP.

EG-Se/Pt induces cell cycle arrest in Jurkat and Molt-4 cells. Disturbance of cell cycle regulation is an important mechanism in the development of T-ALL/LBL (16). To determine whether the inhibitory effect of EG-Se/Pt on cell viability is caused by cell cycle arrest, the effect of EG-Se/Pt on the cell cycle progression of Jurkat and Molt-4 cells was analyzed using flow cytometry. The proportion of Jurkat cells in G1/G0 phase in the presence of 5, 15 and 35 µM EG-Se/Pt was determined to be 32.96, 37.21 and 46.62%, respectively (Fig. 3A and B), and the proportion of Molt-4 cells at S phase in the presence of 5, 12.5 and 25 µM EG-Se/Pt was determined to be 42.49, 49.69 and 59.05%, respectively (Fig. 3A and C). These results demonstrated that EG-Se/Pt induced cell cycle arrest of Jurkat cells at G1/G0 phase (P<0.01) and Molt-4 cells at S phase (P<0.05) in a dose-dependent manner, suggesting that EG-Se/Pt arrests tumor cells in distinct cell cycle phases to inhibit proliferation and induce cell death.

Conclusions

EG-Se/Pt induces apoptosis in Jurkat and Molt-4 cells. To further identify whether apoptosis was responsible for EG-Se/Pt-induced cell death, flow cytometric analysis of annexin V/PI double staining was performed. The apoptotic rates of Jurkat cells in the presence of 5, 15 and 35 µM EG-Se/Pt were determined to be 14.78, 36.07 and 46.52%, respectively (Fig. 4A and B) and the apoptotic rates of Molt-4 cells in the presence of 5, 12.5 and 25 µM EG-Se/Pt were determined to be 13.37, 20.17 and 39.93%, respectively (Fig. 4A and C; P<0.001). These results demonstrated that the apoptotic rates of Jurkat and Molt-4 cells increased in the presence of 15 or 12.5 µM...
Figure 2. Selenium- and platinum-containing compound EG-Se/Pt inhibits the viability of Jurkat and Molt-4 cells. (A) Jurkat and (B) Molt-4 cells were exposed to EG-Se/Pt at various concentrations for 24, 48 and 72 h. (C) Jurkat and (D) Molt-4 cells were treated for 24 h with various concentrations of EG-Se, CDDP and EG-Se/Pt. Cell viability was analyzed using the Cell Counting Kit-8 assay. (E) IC_{50} of EG-Se/Pt and CDDP in Jurkat and Molt-4 cells. Values are presented as the mean ± standard deviation (n=6) of three independent experiments; **P<0.01. CDDP, cis-diamminedichloridoplatinum(II); IC_{50}, half-maximal inhibitory concentration.

Figure 3. Selenium- and platinum-containing compound EG-Se/Pt induces cell cycle arrest in Jurkat and Molt-4 cells. (A) Cell cycle distribution of Jurkat and Molt-4 cells following treatment with various concentrations of EG-Se/Pt for 24 h. Untreated cells served as a control. Percentage of cells in G1/G0, S and G2/M phases in (B) Jurkat and (C) Molt-4 cells. *P<0.05, **P<0.01, ***P<0.001 G1/G0 phase vs. control; #P<0.05, ##P<0.01, ###P<0.001 S phase vs. control.
EG-Se/Pt for 24, 48 and 72 h (Fig. 4D; P<0.01), and that EG-Se/Pt induced apoptosis of Jurkat and Molt-4 cells in a dose- and time-dependent manner.

Intracellular concentrations of Pt are increased in the EG-Se/Pt-treated cells compared with the CDDP-treated cell. To investigate the underlying mechanism of EG-Se/Pt-induced cell death, the intracellular Pt content in the presence of EG-Se/Pt for 24 h was analyzed. The results demonstrated that the intracellular concentration of Pt in Jurkat cells was 28.67 ng/10^6 cells treated with 35 µM EG-Se/Pt and 8.71 ng/10^6 cells treated with 35 µM CDDP. For Molt-4 cells, the concentration of Pt was 32.58 ng/10^6 cells in cells treated with 25 µM EG-Se/Pt and 4.89 ng/10^6 cells in cells treated with 25 µM CDDP. The intracellular concentrations of Pt were markedly increased in the EG-Se/Pt-treated cells compared with the CDDP-treated cells (Fig. 5A; P<0.001). These results suggest that EG-Se/Pt is able to enter tumor cells more efficiently compared with CDDP and that Se-containing polymers are potential redox-responsive drug-delivery vehicles in physiological environments (12).

Apoptosis induced by EG-Se/Pt is dependent on caspase activation. To further investigate the association between apoptosis and EG-Se/Pt-induced cytotoxicity, the apoptotic rates and caspase activity of tumor cells were measured in the presence or absence of the pan-caspase inhibitor z-VAD-FMK. The results demonstrated that z-VAD-FMK almost completely abrogated the induction of apoptosis by EG-Se/Pt (Fig. 5B and C; P<0.01). In the presence of 35 µM EG-Se/Pt, the activity of caspase-3 and caspase-9 in Jurkat cells increased 3.78±0.56 and 5.06±0.63-fold, respectively (Fig. 5D and E; P<0.05), whereas in the presence of 25 µM EG-Se/Pt, the activity of caspase-3 and caspase-9 in Molt-4 cells increased 4.59±0.82 and 5.03±0.80-fold, respectively (Fig. 5F and G; P<0.05). The activity of caspase-3 and caspase-9 inhibited by pretreatment with z-VAD-FMK. These results suggest that the apoptosis induced by EG-Se/Pt is caspase-dependent.

Apoptosis induced by EG-Se/Pt is dependent on ROS generation and mitochondrial membrane potential disruption. A preliminary study demonstrated that the activity of caspase-9 in Jurkat and Molt-4 cells increased markedly in the presence of EG-Se/Pt (data unpublished). Therefore, it is suggested that the EG-Se/Pt-induced apoptosis was associated with the mitochondrial signaling pathway and intracellular ROS and MMP was investigated using flow cytometry. Pretreatment with NAC, an antioxidant, prior to treatment with EG-Se/Pt blocked the majority of the apoptotic activity of EG-Se/Pt (Fig. 6A; P<0.05), indicating that EG-Se/Pt-induced apoptosis was mediated by ROS.

The ROS levels induced by EG-Se/Pt were measured in Jurkat and Molt-4 cells. The ROS levels following treatment of
Jurkat cells with 5, 15 and 35 µM EG-Se/Pt, and Molt-4 cells with 5, 12.5 and 25 µM EG-Se/Pt, for 24 h were 19.41, 15.15 and 40.59%, respectively, for Jurkat cells, and 27.70, 44.53 and 86.03%, respectively, for Molt-4 cells (Fig. 6B; P<0.01). These results demonstrate that EG-Se/Pt markedly increases ROS generation in Jurkat and Molt-4 cells in a dose-dependent manner.

To assess the role of mitochondria in EG-Se/Pt-induced apoptosis, MMP was determined in the cell lines using JC-1 staining. As presented in Fig. 6C (P<0.01), the level of MMP in Jurkat cells was 84.13, 71.70 and 44.78% following 24 h treatment with 5, 15 and 35 µM EG-Se/Pt, respectively. Similarly, the level of MMP in Molt-4 cells treated with 5, 12.5 and 25 µM EG-Se/Pt for 24 h was 85.25, 49.25 and 21.86%, respectively.

In the ROS inhibitor group, pretreatment with 10 mM NAC prior to treatment with EG-Se/Pt almost completely inhibited the disruption of MMP (Fig. 6C). These results suggest that EG-Se/Pt-induced apoptosis is associated with ROS generation and MMP disruption.

**EG-Se/Pt induces apoptosis via a mitochondria-dependent pathway.** A preliminary study demonstrated that the apoptosis induced by EG-Se/Pt was associated with ROS generation, MMP disruption and caspase-9 activation (data unpublished). It is hypothesized that EG-Se/Pt induced apoptosis through a mitochondrial signaling pathway. To verify this hypothesis, the expression of several critical proteins was examined in the mitochondrial apoptosis pathway using western blot analysis.
following 24 h treatment of cells with various concentrations of EG-Se/Pt. It is well known that the Bcl-2 protein family, cytochrome c, Apaf-1, caspase-9, caspase-3 and PARP serve important roles in mitochondrially mediated apoptosis (17). As shown in Fig. 7, EG-Se/Pt induced the upregulation of Bax, cytosolic cytochrome c, Apaf-1, cleaved caspase-9, cleaved caspase-3 and cleaved PARP, and downregulation of Bcl-2 and mitochondrial cytochrome c, in a dose- and time-dependent manner in Jurkat and Molt-4 cells.

**Discussion**

CDDP has been demonstrated to be effective in the treatment of cancer; however, serious adverse reactions to CDDP are well-known (5). CDDP and other Pt-containing compounds serve an important role in the treatment of T-ALL/LBL (3,4,6). EG-Se/Pt is a novel agent that demonstrates increased selectivity between cancer cells and wild-type cells compared with CDDP, through the generation of excessive ROS (11,12). To the best of our knowledge, the present study was the first to demonstrate that EG-Se/Pt is toxic to the Jurkat and Molt-4 T-ALL/LBL cell lines *in vitro*. The results of the present study demonstrated that treatment with EG-Se/Pt resulted in a marked decrease in the viability and a marked increase in the apoptosis of tumor cells in a concentration- and time-dependent manner compared with the control. EG-Se/Pt is a derivative of CDDP, therefore the inhibitory effects on proliferation following treatment with EG-Se/Pt and CDDP were compared. It was demonstrated that EG-Se/Pt exhibited increased cytotoxicity compared with CDDP at the same concentration. To investigate the underlying mechanism, the intracellular concentrations of Pt were evaluated. The EG-Se/Pt-treated cell lines demonstrated increased Pt levels compared with the CDDP-treated cell lines, consistent with a previous study in
liver cancer, breast cancer and lung adenocarcinoma cells (12). These results suggested that EG-Se/Pt may enter cells efficiently compared with CDDP as Se-containing polymers demonstrated potential as redox-responsive drug-delivery vehicles (12), and that the increased cytotoxicity may be associated with the increased Pt concentration in cancer cells. A previous study has demonstrated that EG-Se/Pt selectively kills liver cancer cells via ROS-mediated apoptosis with minor effects on the viability of wild-type liver cells (12). Due to a lack of access to wild-type T-cell lines, the inhibitory effect on proliferation between wild-type and malignant T cells were not compared in the present study.

It is well-known that disturbance of cell cycle regulation is responsible for the initiation and formation of hematological tumors, including mantle cell lymphoma and T-ALL/LBL (16,18). Anticancer drugs induce cell cycle arrest at a specific checkpoint and thereby induce cell death (16,19,20). In the present study, it was demonstrated that EG-Se/Pt induced Jurkat cell arrest at the G1/G0 phase and Molt-4 cell arrest at the S phase in a dose-dependent manner, suggesting that cell cycle arrest is one of the underlying molecular mechanisms for the inhibitory effects of EG-Se/Pt on tumor cells. It is notable that EG-Se/Pt arrests Jurkat and Molt-4 cells at distinct cell cycle phases. As wild-type p53 protein blocks cells at the G1/G0 and G2/M phase through distinct downstream genes (21,22), it is hypothesized that this difference may be associated with the p53 gene deletion in Molt-4 cells and this hypothesis will be tested in future studies.

Apoptosis is a major mechanism of cell death and serves a key role in the elimination of tumor cells. The results of the present study demonstrated that EG-Se/Pt induced T-ALL/LBL cell apoptosis in a concentration- and time-dependent manner, which is consistent with previous results for liver, breast, lung and colon cancer cells (12). Members of the caspase protein family serve a central role in the initiation and execution of apoptosis. In particular, caspase-9 triggers the intrinsic apoptotic cascade and caspase-3 acts as a key executor in cell apoptosis (23). Cells were treated with the pan-caspase inhibitor z-VAD-FMK prior to treatment with EG-Se/Pt, and it was identified that the apoptotic rate and the activity of caspase-3 and caspase-9 were decreased. These results demonstrated that EG-Se/Pt induced apoptosis of Jurkat and Molt-4 cells in a caspase-dependent manner, which is in contrast with a preliminary study on other tumors demonstrating that EG-Se/Pt induces apoptosis without caspase-3 activation (12). However, it was also demonstrated that z-VAD-FMK did not rescue all of the cells but instead led to apoptotic rates that were increased relative to those of the control group, indicating that cell death independent of caspase also exists and requires further study.

There are two primary apoptotic signaling pathways: The death receptor signaling pathway and the mitochondrial signaling pathway (24). Increased levels of ROS may induce cell apoptosis by disrupting the intracellular redox balance and activating the mitochondrial pathway (17,25). The efficacy of inorganic and organic Se compounds as cancer chemotherapeutic compounds via the generation of ROS has been demonstrated (26). CDDP also induces ROS that trigger mitochondrial apoptosis (6). EG-Se/Pt is a novel compound that is self-assembled from EG-Se and CDDP. A previous study indicated that EG-Se/Pt induced cell apoptosis through the generation of excessive ROS (12). ROS disrupt the MMP through mitochondrial outer membrane permeabilization and inducing Bax dimerization (17). Subsequently, cytochrome c enters the cytosol, binds to Apaf-1 and activates caspase-9, leading to activation of the executioner caspase-3 (17). Pretreatment with NAC, a scavenger of ROS, significantly decreased MMP disruption and apoptosis, indicating that the apoptosis induced by EG-Se/Pt is associated with ROS levels. However, apoptosis was not completely inhibited by NAC, suggesting that ROS-independent pathways also participate in cell death.

In conclusion, it is hypothesized that EG-Se/Pt inhibits proliferation and induces apoptosis of Jurkat and Molt-4 cells through the mitochondrial signaling pathway by generating excessive ROS that disrupt the MMP. EG-Se/Pt is a potential anticancer drug for T-ALL/LBL therapy. Future studies are required to investigate the effects of EG-Se/Pt on CDDP-resistant tumor cells in vitro and in vivo, and further elucidate the underlying molecular mechanism of cell death induced by EG-Se/Pt.

Acknowledgements

The authors of the present study thank Dr Jing Wang of Peking University Third Hospital (Beijing, China) for assisting with the preparation of the present paper.
References

1. Ellin F, Jerekman M, Hagberg H and Relander T: Treatment outcome in T-cell lymphoblastic lymphoma in adults-a population-based study from the Swedish Lymphoma Registry. Acta Oncol 53: 927-934, 2014.

2. Puig N, Wang L, Seshadri T, al-Farsi K, Keating A, Crump M and Kuruvilla J: Treatment response and overall outcome of patients with relapsed and refractory peripheral T-cell lymphoma compared to diffuse large B-cell lymphoma. Leuk Lymphoma 54: 507-513, 2013.

3. Michot J, Mazeron R, Danu A, Lazarovici J, Gher D, Antosikova A, Willekens C, Chamseddine AN, Minard V, Dartigues P, et al: Concurrent etoposide, steroid, high-dose arsenic trioxide (ros)-mediated apoptosis route. Zhonghua Xue Ye Xue Za Zhi 37: 1295-2302, 2014.

4. Mahadevan D, Unger JM, Spier CM, Persky DO, Young F, LeBlanc M, Fisher RJ and Miller TP: Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest oncology group study S0350. Cancer 119: 371-379, 2013.

5. Hill NO: cis-platinum for cancer. New Engl J Med 301: 47, 1979.

6. Dasari S and Iyer S: Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol 740: 364-378, 2014.

7. McKeage MJ: New-generation platinum drugs in the treatment of cisplatin-resistant cancers. Expert Opin Investig Drugs 14: 1033-1046, 2005.

8. Last K, Maharaj L, Perry J, Strauss S, Fitzgibbon J, Lister TA and Joel S: The activity of methylated and non-methylated selenium species in lymphoma cell lines and primary tumours. Ann Oncol 17: 773-779, 2006.

9. Jiang C, Wang Z, Ganther H and Liu J: Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle and protein kinase pathways in du145 human prostate cancer cells. Mol Cancer Ther 1: 1059-1066, 2002.

10. Wang Z, Jiang C and Liu J: Induction of caspase-mediated apoptosis and cell-cycle G1 arrest by selenium metabolite methylselenol. Mol Carcinog 34: 113-120, 2002.

11. Husbeck B, Nonn L, Peehl DM and Knox SJ: Tumor-selective killing by selenite in patient-matched pairs of normal and malignant prostate cells. Prostate 66: 218-225, 2006.

12. Zeng L, Li Y, Li T, Cao W, Yi Y, Geng W, Sun Z and Xu H: Selenium-platinum coordination compounds as novel anticancer drugs: Selectively killing cancer cells via a reactive oxygen species (ros)-mediated apoptosis route. Chem Asian J 9: 2295-2302, 2014.

13. Wang K, Chen X, Wuxiao Z, Wang Z, Sun X, Zeng Z, Li S and Xia ZJ: Long-term outcomes of modified Berlin-Frankfurt-Münster-90 regimen in adults with T-lymphoblastic lymphoma: A single-center experience. Leuk Lymphoma 55: 1800-1805, 2014.

14. Sharma V, Anderson D and Dhawan A: Zinc oxide nanoparticles induce oxidative DNA damage and ROS-triggered mitochondria mediated apoptosis in human liver cells (HeP2G2). Apoptosis 17: 852-870, 2012.

15. Akhtar MJ, Ahamed M, Kumar S, Khan MM, Ahmad J and Alrokayya SA: Zinc oxide nanoparticles selectively induce apoptosis in human cancer cells through reactive oxygen species. Int J Nanomedicine 7: 845-857, 2012.

16. Bonn BR, Krieger D and Burkhardt B: Cell cycle regulatory molecular profiles of pediatric T-cell lymphoblastic leukemia and lymphoma. Leuk Lymphoma 53: 557-568, 2012.

17. Tait SW and Green DR: Mitochondrial regulation of cell death. Cold Spring Harb Perspect Biol 5: pii: a008706, 2013.

18. Yang WJ, Yu Z and Qiu LG: Research advances of signal pathway in the pathogenesis of mantle cell lymphoma. Zhonghua Xue Ye Xue Za Zhi 34: 1073-1075, 2013 (In Chinese)

19. Gopal PK, Paul M and Paul S: Curcumin induces caspase mediated apoptosis in JURKAT cells by disrupting the redox balance. Asian Pac J Cancer Prev 15: 93-100, 2014.

20. Sánchez-Martínez C, Gelbert LM, Lallena MJ and de Dios A: Cyclin dependent kinase (CDK) inhibitors as anticancer drugs. Bioorg Med Chem Lett 25: 3420-3425, 2015.

21. Levine AJ, Perry ME, Chang A, Silver A, Dittmer D, Wu M and Welsh D: The 1993 Walter Hubert Lecture: The role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer 69: 409-416, 1994.

22. Laronga C, Yang HY, Neal C and Lee MH: Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progression. J Biol Chem 275: 23106-23112, 2000.

23. Wu C and Bratton SB: Regulation of the intrinsic apoptosis pathway by reactive oxygen species. Antioxid Redox signal 19: 546-558, 2013.

24. Kiraz Y, Adan A, Kartal Yandim M and Baran Y: Major apoptotic mechanisms and genes involved in apoptosis. Tumour Biol 37: 8471-8486, 2016.

25. Liou G and Storz P: Reactive oxygen species in cancer. Free Radical Res 44: 479-496, 2010.

26. Zeng H and Combs GF Jr: Selenium as an anticancer nutrient: Roles in cell proliferation and tumor cell invasion. J Nutr Biochem 19: 1-7, 2008.